1976
DOI: 10.1159/000231534
|View full text |Cite
|
Sign up to set email alerts
|

Inhibition of Allergic Reactions by Cromoglycate and by a New Anti-Allergic Drug (10-Chloro-1,4,6,9-Tetrahydro-4,6-Dioxopyrido[3,2-g]Quinoline-2,8-Dicarboxylic Acid)

Abstract: A new inhibitor of IgE-mediated allergic reactions has been studied in rats. This new inhibitor is chemically quite different from cromoglycate and shows qualitative and quantitative advantages over it. This new inhibitor possesses no bronchodilator or end-organ antagonism activity, but as cromoglycate acts by inhibition of mediator release. Multiple doses in rats lead to tachyphylaxis. This effect is reversed both by decreasing the first dose and increasing the time between doses.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

5
3
0

Year Published

1976
1976
1986
1986

Publication Types

Select...
7
3

Relationship

3
7

Authors

Journals

citations
Cited by 14 publications
(8 citation statements)
references
References 6 publications
5
3
0
Order By: Relevance
“…While there may be some quantitative differences, in effect this significantly more active com pound [Hall et al, 1975] (fig. 1), exhibits many features similar to DSCG and other similar previously reported compounds [Johnson and VanHout, 1976],…”
supporting
confidence: 80%
“…While there may be some quantitative differences, in effect this significantly more active com pound [Hall et al, 1975] (fig. 1), exhibits many features similar to DSCG and other similar previously reported compounds [Johnson and VanHout, 1976],…”
supporting
confidence: 80%
“…Our finding that DSCG diminished the severity of the Ascaris-induced respiratory changes in the conscious monkey corrobor ates those of Johnson and Van Hout [2] and Patterson et al [7], who studied anesthe tized animals. Since the in vitro inhibiting action of DSCG in antigen-stimulated his tamine release in chopped monkey lung and bronchi has been documented [10], it sug gests the primary action of this agent, in the monkey, is attenuation of mast cell histam ine release.…”
Section: Discussionsupporting
confidence: 92%
“…PRD-92-Ea inhibited the PCA reaction in the rat after oral administration but higher doses were required than those given intravenously. DSCG was completely inactive in the rat when given orally in doses up to 300 mg/kg and this finding agrees with the ex perience of others [9,17,18]. In the results to be published elsewhere [5] PRD-92-Ea exhibited tachyphylaxis in the rat PCA af ter intravenous predosing and cross-react ing tachyphylaxis after predosing with DSCG.…”
Section: Discussionsupporting
confidence: 91%